Second Indian generics deal for SA's Litha, this one with Micro Labs

In a second deal with an Indian drugmaker, South Africa’s Litha Healthcare has signed an exclusive agreement with Micro Labs, a leading Indian generic pharmaceutical manufacturer which boasts a network of 11 manufacturing sites in India.

The accord includes a range of quality generic pharmaceutical products developed and manufactured by Micro Labs. Explaining Litha’s rationale in partnering with the Indian manufacturer, chief executive, Selwyn Kahanovitz, said: “We have been anticipating this deal which will enable us not only to expand our pharma product portfolio, but to offer the South African public access to more quality medicines targeting infectious as well as chronic diseases.”

He added:”The strategic significance of this agreement is substantial. Litha Pharma will now be able to target a wider range of therapeutic areas, specifically where there is scope for growth and a need for NDDS’s (Novel Drug Delivery Systems).”